
    
      Multicenter, prospective, single arm trial - Up to seven hundred (700) aortic valve
      replacement (AVR) subjects and up to one hundred seventy-five (175) mitral valve replacement
      (MVR) subjects at up to forty (40) clinical sites will be enrolled. The trial will include
      male and female patients, 18 years or older, requiring replacement for a diseased, damaged,
      or malfunctioning native or prosthetic aortic or mitral valve. Patients will be followed and
      assessed after implant for up to 5 years.
    
  